RxDoctor Payments Data

Alan Klein, MD

Internal Medicine · Neptune, NJNPI 1710069471

Payments from drug & device makers

$2,108in general payments, 2019–2025

Across 68 payments — averaging $31.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$656
  • Amgen$601
  • Pfizer$275
  • Novartis$146
  • Exact Sciences$98
  • Phathom Pharmaceuticals, Inc.$43
  • plus $289 from 14 others

What the payments were for

  • Food & beverage$2,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,108 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$297,909
Medicare patients
522
Services billed
3,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab78$46,760
OzempicSemaglutide40$35,550
EliquisApixaban34$28,392
MounjaroTirzepatide26$27,484
TradjentaLinagliptin29$21,186
XareltoRivaroxaban13$8,366
Atorvastatin Calcium490$5,490
Levothyroxine Sodium348$4,052
SynthroidLevothyroxine Sodium45$3,687
Ezetimibe120$3,589
Valsartan93$3,539
Metoprolol Succinate165$2,961
Rosuvastatin Calcium152$2,620
Amlodipine Besylate322$2,513
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$1,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21$35,55040 claims
PfizerEliquis$275$28,39234 claims
Boehringer IngelheimTradjenta$26$21,18629 claims
Johnson & JohnsonXarelto$15$8,36613 claims
AbbVieSynthroid$36$3,68745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →